Literature DB >> 17317669

Estrogen receptor alpha and the activating protein-1 complex cooperate during insulin-like growth factor-I-induced transcriptional activation of the pS2/TFF1 gene.

Sylvain Baron1, Aurélie Escande, Géraldine Albérola, Kerstin Bystricky, Patrick Balaguer, Hélène Richard-Foy.   

Abstract

Insulin like growth factor I (IGF-I) displays estrogenic activity in breast cancer cells. This activity is strictly dependent on the presence of estrogen receptor alpha (ERalpha). However the precise molecular mechanisms involved in this process are still unclear. IGF-I treatment induces phosphorylation of the AF1 domain of ERalpha and activation of estrogen regulated genes. These genes are characterized by important differences in promoter architecture and response element composition. We show that promoter structure is crucial for IGF-I-induced transcription activation. We demonstrate that on a complex promoter such as the pS2/TFF1 promoter, which contains binding sites for ERalpha and for the activating protein-1 (AP1) complex, transcriptional activation by IGF-I requires both ERalpha and the AP1 complex. IGF-I is unable to stimulate transcription of an estrogen-regulated gene under the control of a minimal promoter containing only a binding site for ERalpha. We propose a molecular mechanism with stepwise assembly of the AP1 complex and ERalpha during transcription activation of pS2/TFF1 by IGF-I. IGF-I stimulation induces rapid phosphorylation and an increase in protein levels of the AP1 complex. Binding of the phosphorylated AP1 complex to the pS2/TFF1 promoter allows recruitment of the chromatin remodeling factor Brg1 followed by binding of ERalpha via its interaction with c-Jun.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17317669     DOI: 10.1074/jbc.M610079200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  11 in total

1.  Cadmium promotes breast cancer cell proliferation by potentiating the interaction between ERalpha and c-Jun.

Authors:  Christina L Siewit; Bridget Gengler; Esera Vegas; Rachel Puckett; Maggie C Louie
Journal:  Mol Endocrinol       Date:  2010-03-10

2.  Tamoxifen increases nuclear respiratory factor 1 transcription by activating estrogen receptor beta and AP-1 recruitment to adjacent promoter binding sites.

Authors:  Margarita M Ivanova; Kristen H Luken; Amber S Zimmer; Felicia L Lenzo; Ryan J Smith; Maia W Arteel; Tara J Kollenberg; Kathleen A Mattingly; Carolyn M Klinge
Journal:  FASEB J       Date:  2011-01-13       Impact factor: 5.191

3.  The role for estrogen receptor-alpha and prolactin receptor in sex-dependent DEN-induced liver tumorigenesis.

Authors:  Robert M Bigsby; Andrea Caperell-Grant
Journal:  Carcinogenesis       Date:  2011-05-23       Impact factor: 4.944

4.  Activation of thyroid hormone is transcriptionally regulated by epidermal growth factor in human placenta-derived JEG3 cells.

Authors:  Gianluca Canettieri; Antonella Franchi; Michele Della Guardia; Ianessa Morantte; Maria Giulia Santaguida; John W Harney; P Reed Larsen; Marco Centanni
Journal:  Endocrinology       Date:  2007-11-08       Impact factor: 4.736

5.  RhoA and RhoC differentially modulate estrogen receptor α recruitment, transcriptional activities, and expression in breast cancer cells (MCF-7).

Authors:  Emilie Malissein; Elise Meunier; Isabelle Lajoie-Mazenc; Claire Médale-Giamarchi; Florence Dalenc; Sophie F Doisneau-Sixou
Journal:  J Cancer Res Clin Oncol       Date:  2013-10-06       Impact factor: 4.553

6.  Hormonally responsive breast cancer cells in a microfluidic co-culture model as a sensor of microenvironmental activity.

Authors:  Jessica D Lang; Scott M Berry; Ginny L Powers; David J Beebe; Elaine T Alarid
Journal:  Integr Biol (Camb)       Date:  2013-05       Impact factor: 2.192

7.  Trefoil factor 1 in early breast carcinoma: a potential indicator of clinical outcome during the first 3 years of follow-up.

Authors:  Milan Markićević; Radan Džodić; Marko Buta; Ksenija Kanjer; Vesna Mandušić; Zora Nešković-Konstantinović; Dragica Nikolić-Vukosavljević
Journal:  Int J Med Sci       Date:  2014-05-01       Impact factor: 3.738

8.  TOX3 is expressed in mammary ER(+) epithelial cells and regulates ER target genes in luminal breast cancer.

Authors:  Akop Seksenyan; Asha Kadavallore; Ann E Walts; Brian de la Torre; Dror Berel; Samuel P Strom; Parinaz Aliahmad; Vincent A Funari; Jonathan Kaye
Journal:  BMC Cancer       Date:  2015-01-30       Impact factor: 4.430

9.  RhoB modifies estrogen responses in breast cancer cells by influencing expression of the estrogen receptor.

Authors:  Claire Médale-Giamarchi; Isabelle Lajoie-Mazenc; Emilie Malissein; Elise Meunier; Bettina Couderc; Yann Bergé; Thomas Filleron; Laura Keller; Claudine Marty; Magali Lacroix-Triki; Florence Dalenc; Sophie F Doisneau-Sixou; Gilles Favre
Journal:  Breast Cancer Res       Date:  2013-01-22       Impact factor: 6.466

10.  Growth of poorly differentiated endometrial carcinoma is inhibited by combined action of medroxyprogesterone acetate and the Ras inhibitor Salirasib.

Authors:  Raya Faigenbaum; Roni Haklai; Gilad Ben-Baruch; Yoel Kloog
Journal:  Oncotarget       Date:  2013-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.